ProfileGDS5678 / 1416838_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 83% 85% 84% 86% 87% 85% 86% 88% 86% 86% 86% 85% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4772486
GSM967853U87-EV human glioblastoma xenograft - Control 26.0633283
GSM967854U87-EV human glioblastoma xenograft - Control 36.4013485
GSM967855U87-EV human glioblastoma xenograft - Control 46.4466184
GSM967856U87-EV human glioblastoma xenograft - Control 56.4981586
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4512887
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2109485
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5300886
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8116588
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5709486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5084186
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6004586
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2994185
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.4547286